Full identifier: http://purl.org/np/RApHsKFnbSdWEl86GviCOj-qg9IDUR9AvvMRF8bO4DHLU#assertion
| Nanopublication | Part | Subject | Predicate | Object | Published By | Published On |
|---|---|---|---|---|---|---|
|
links a nanopublication to its provenance
http://www.nanopub.org/nschema#hasProvenance
provenance
|
assertion
|
Elif Ozkan
|
2022-10-13T12:35:21.230Z
|
|||
|
links a nanopublication to its provenance
http://www.nanopub.org/nschema#hasProvenance
provenance
|
assertion
|
2022-10-13T12:35:21.230396
|
Elif Ozkan
|
2022-10-13T12:35:21.230Z
|
||
|
links a nanopublication to its provenance
http://www.nanopub.org/nschema#hasProvenance
provenance
|
assertion
|
Atorvastatin and other statins are considered first-line treatment options for dyslipidemia. The increasing use of this class of drugs is largely attributed to the rise in cardiovascular diseases (CVD) An elevated cholesterol level (elevated low-density lipoprotein (LDL) levels) is a significant risk factor for the development of CVD. Statins were shown to reduce the incidences of all-cause mortality, including fatal and non-fatal CVD, as well as the need for surgical revascularization or angioplasty following a
|
Elif Ozkan
|
2022-10-13T12:35:21.230Z
|